Dr Aris Angelis

Dr Aris Angelis

Research Officer LSE Health and Guest Teacher/Lecturer Department of Health Policy

LSE Health

Telephone
+44 (0)20 7955 6842
Room No
KGS 3.02
Connect with me

Languages
English
Key Expertise
Health Policy

About me

Dr Aris Angelis is a Researcher at the Medical Technology Research Group, LSE Health and a Guest Teacher/Lecturer at the Department of Health Policy, at the London School of Economics and Political Science (LSE).

His research focuses on the areas of pharmaceutical policy and health technology assessment (HTA). His academic interests include methodological research around the evaluation of new medical technologies, the research and development (R&D) process of new biopharmaceutical interventions and the pharmaceutical regulation systems.

Aris received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the Department of Social Policy (LSE Health) at LSE. His PhD investigated the development and application of a methodological framework based on Multiple Criteria Decision Analysis (MCDA) for assessing the value of new medical technologies in the context of HTA, to inform resource allocation decisions and incentivise socially desirable R&D investments.

Aris has undertaken contracted research, training and advisory work for the European Commission, the World Health Organisation, national health ministries and various biopharmaceutical organisations. Aris’ past work experience includes intern roles at Novartis and the Greek National Organization for Medicines. He holds an MSc in International Health Policy - Health Economics from the LSE, an MSc in Biopharmacy from King’s College London and a BSc in Biochemistry from Imperial College London.

Publications

For a complete list of Aris's publications, see Google Scholar and LSE Research Online.

Follow Aris on Twitter

Teaching

  • HP424 Pharmaceutical Economics and Policy
  • HP4B1E Pharmaceutical Economics and Policy
  • HP4D2E Principles of Health Technology Assessment

Expertise Details

Pharmaceutical Policy; Health Technology Assessment